Notably, pharmacological melatonin has been shown to significantly downregulate LSD1 in LSD1-overexpressing oral cancer patient-derived tumor xenografts and oral cancer cell lines, in addition to arresting the cell cycle at the G0/G1 phase and decreasing cell proliferation in a dose- and time-dependent manner. The gene discussed is KDM1A; the disease is lip and oral cavity carcinoma.